This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

GZS Announces Worldwide Release Of Hemaglobal™ EHR Patient Registry Solution For Hemophilia And Bleeding Disorders

HemaGlobal covers a large spectrum of bleeding and clotting disorders, including von Willebrand disease, congenital afibrinogenemia, Glanzmann's thrombasthenia, Bernard-Soulier syndrome, hemophilia and other factor deficiencies.

HemaGlobal makes it easy for hemophilia treatment centers to organize, analyze and manage patient information in detail using standardized nomenclature.  It establishes a secure and timely data exchange that enables physicians to eliminate traditional IT and procedural bottlenecks as they share patient information with multi-disciplinary team members.  The user interface is intuitive and requires little more than basic computing skills.

About GZS

In the early 1980s, the CDC referred to San Francisco as "Ground Zero" in the AIDS epidemic. We embraced the name "Ground Zero Software" and launched *Lab Tracker for HIV, our first Electronic Medical Record (EMR), in 1993.

Since then, GZS has been a pioneer and leader in developing disease-specific and condition-specific EMR/EHR patient registry software solutions to the worldwide healthcare industry.  The company's current product offerings are specific to Hemophilia and bleeding disorders, Spina Bifida, and are readily adapted to other diseases and conditions.  GZS has a large customer base of universities, government and non-government organizations, pharmaceutical, diagnostics, and healthcare providers of all sizes in the U.S., South America and Africa.

www.HemaGlobal.com info@hemaglobal.com

*Lab Tracker-HIV was acquired by Virco Labs, Inc. (now Janssen Diagnostics, Inc.) in December, 2009

HemaGlobal and HemoGlobal are registered trademarks of Ground Zero Software, Inc.

For more information: John HollisGZS Corporate Communications+1-760-327-2333 www.hemaglobal.com  info@hemaglobal.com

SOURCE GZS, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs